SK
Sumit Kariwala
About Sumit Kariwala
Data last updated:
Sumit Kariwala is an Additional Director at Unimed Drugs Pvt Ltd (since 2022) and Designated Partner at Dhaamak Natural Llp (since 2026). The companies operate in Chemicals. The largest current company by reported revenue is Unimed Drugs Pvt Ltd at ₹35,690 (FY 2017).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Unimed Drugs Pvt Ltd U24232WB1987PTC042256 | Additional Director | 08 Feb 2022 | 1987 | ₹35,690 (FY 2017) | Active |
| Dhaamak Natural Llp ADB-1878 | Designated Partner | 13 Aug 2026 | 2026 | Active |
Board colleagues of Sumit Kariwala
| Name | DIN | Company | Designation |
|---|---|---|---|
| Sangita Kariwala | 09490461 | Unimed Drugs Pvt Ltd , Dhaamak Natural Llp | Additional Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sumit Kariwala
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sumit Kariwala
Sumit Kariwala currently holds 2 directorships: Unimed Drugs Pvt Ltd (Additional Director, since 08 Feb 2022, revenue ₹35,690 (FY 2017)); Dhaamak Natural Llp (Designated Partner, since 13 Aug 2026).
Sumit Kariwala was first appointed on 08 Feb 2022 as Additional Director at Unimed Drugs Pvt Ltd. The most recent appointment on record is 13 Aug 2026 at Dhaamak Natural Llp.
The current boards of Sumit Kariwala's companies include Sangita Kariwala (Unimed Drugs Pvt Ltd).